Biotech companies often linger in a corporate version of Schrödinger’s box — of existence and un-existence — for quite some time before officially announcing a “launch.”
Sana Biotechnology, for example, spent a year in limbo before its communications team sent out a press release announcing its launch last October. Thrive Earlier Detection Corp. had its corporate ducks in a row for more than a month before it announced itself. There’s no telling just how many potential biotechs are as-yet-unlaunched, though it’s enough to keep the biotech trade press busy.
On Tuesday, the belle of the launch ball was gene editing company Prime Medicine — which “launched” despite the fact that news of the company’s existence broke more than a year ago, via Beam Therapeutics’ September 2019 IPO filing and a subsequent press release.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
